Following Ujjivan’s earnings, several top brokerages recommended a ‘Buy’ stance on the counter. While Emkay retained its buy rating on for a target price of Rs 58, HDFC Securities has an ‘Add’ recommendation for a target of Rs 50. ICICI Securities was most bullish in terms of targets and pegged it at Rs 60.
Biocon buys back an investor stake in biologics unit, posts Rs 25 crore net profit in Q3FY25
Biocon’s board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected